The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Insmed Incorporated (NASDAQ:INSM) is among the Best Healthcare Stocks.

On June 15, Mizuho lowered its price target on Insmed Incorporated (NASDAQ:INSM) to $192 from $202. It maintained an Outperform rating on the shares. The firm stated the recent selloff created a buying opportunity even though shares have fallen 29% since the company's first-quarter report.

Mizuho found the sharp move in investor sentiment "shocking" and expressed confidence in both Insmed and BRINSUPRI.

Separately, on June 23, Insmed Incorporated (NASDAQ:INSM) announced that it appointed Samuele Butera as Senior Vice President and General Manager, Global Respiratory, effective immediately. He will lead the firm's Respiratory Therapeutic Area, report to Chair and CEO Will Lewis, and join the executive committee.

Lewis said Butera's commercial leadership experience would support the launch of BRINSUPRI, the potential label expansion of ARIKAYCE, and the development of the TPIP program.

Butera called it "a defining moment" for the biopharmaceutical firm. He plans to help advance BRINSUPRI, expand ARIKAYCE, and continue developing TPIP and other pipeline candidates.

Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company that produces and markets medicines for rare diseases. It focuses on the Brensocatib and Treprostinil Palmitil Inhalation Powder pipelines.

While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.